Wells Fargo’s TransCode Therapeutics RNAZ Stock Holding History

Wells Fargo’s Portfolio RNAZ Stock Details RNAZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$474	Buy	+55	New	+$513	﹤0.01%	6400
2024 Q2	–	Hold	0	–	-$3	–	7368
2024 Q1	–	Hold	0	–	–	–	7437
2023 Q4	–	Hold	0	–	–	–	7127
2023 Q3	–	Hold	0	–	–	–	7465
2023 Q2	–	Hold	0	–	–	–	7466
2023 Q1	–	Hold	0	–	–	–	7411
2022 Q4	–	Hold	0	–	–	–	7126
2022 Q3	–	Hold	0	–	–	–	7242
2022 Q2	–	Hold	0	–	–	–	7367
2022 Q1	–	Hold	0	–	–	–	7683
2021 Q4	–	Hold	0	–	–	–	7704
2021 Q3	–	Hold	0	–	–	–	7416

Other funds holding RNAZ

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Wells Fargo's RNAZ Position: Q1 2026 in Review

Wells Fargo opened a new position in TransCode Therapeutics (RNAZ) in Q1 2026: 55 shares worth $474. The stake represents ﹤0.01% of the portfolio and ranks #6400 among its holdings.

8 funds tracked by Wall St. Rank hold RNAZ as of Q1 2026.

Wells Fargo held 55 shares of TransCode Therapeutics worth $474 as of Q1 2026.
TransCode Therapeutics was a new Wells Fargo position in Q1 2026.
TransCode Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6400 holding.
8 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.